Published in Clin Cancer Res on March 15, 2007
Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer (2010) 1.07
The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer (2009) 0.87
Differential expression of cancer associated proteins in breast milk based on age at first full term pregnancy. BMC Cancer (2012) 0.81
Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model. PLoS One (2011) 0.81
OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery. Oncol Lett (2014) 0.81
Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. J Gynecol Oncol (2012) 0.79
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiol Oncol (2013) 0.75
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet (2010) 5.48
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28
Differences between tight and loose cultures: a 33-nation study. Science (2011) 3.47
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov (2008) 2.80
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol (2008) 2.80
A meta-analysis on the correlation between the implicit association test and explicit self-report measures. Pers Soc Psychol Bull (2005) 2.59
Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol (2005) 2.54
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol (2006) 2.48
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer (2010) 2.43
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer (2004) 2.38
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol (2010) 2.19
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs (2007) 2.08
First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT. Eur J Nucl Med Mol Imaging (2010) 2.07
Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. Clin Chem Lab Med (2014) 2.03
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res (2013) 1.89
SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis (2008) 1.84
Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res (2012) 1.73
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat (2008) 1.68
Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem (2007) 1.66
Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics (2007) 1.65
Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem (2006) 1.63
Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res (2004) 1.63
St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) (2011) 1.62
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci (2006) 1.59
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res (2007) 1.57
POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? Clin Biochem (2007) 1.56
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol (2006) 1.54
More discussion on journal impact factor. Clin Chem Lab Med (2013) 1.53
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 1.51
The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol (2010) 1.50
B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res (2006) 1.50
Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol (2008) 1.50
Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer (2004) 1.49
Short tandem repeat polymorphism and cancer risk: influence of laboratory analysis on epidemiologic findings. Cancer Epidemiol Biomarkers Prev (2004) 1.49
Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res (2010) 1.48
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol (2008) 1.47
Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist (2008) 1.47
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat (2010) 1.47
Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer. Onkologie (2009) 1.45
A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol (2012) 1.44
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer (2002) 1.44
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology (2010) 1.42
Theranos phenomenon: promises and fallacies. Clin Chem Lab Med (2015) 1.42
Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer. Onkologie (2007) 1.41
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. Tumour Biol (2005) 1.41
Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem (2012) 1.41
[Re: Kay Brune. Altex 19, 3, 2002: Animal experimentation in sciences: sadistic nonsense or indispensible necessity?]. ALTEX (2002) 1.40
Association between Echinococcus granulosus infection and cancer risk - a pilot study in Cyprus. Clin Chem Lab Med (2016) 1.39
Working memory capacity and self-regulatory behavior: toward an individual differences perspective on behavior determination by automatic versus controlled processes. J Pers Soc Psychol (2008) 1.38
Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study. BMC Cancer (2006) 1.38
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer (2009) 1.37
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res (2008) 1.37
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol (2003) 1.37
The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem (2009) 1.36
Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst (2008) 1.36
Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One (2008) 1.35
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res (2005) 1.34
Functional roles of human kallikrein-related peptidases. J Biol Chem (2009) 1.33
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics (2008) 1.32
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem (2010) 1.32
A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem (2006) 1.31
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol (2006) 1.31
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol (2009) 1.31
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer (2011) 1.30
Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol (2002) 1.30
Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem (2011) 1.30
Proteomic analysis of seminal plasma from normal volunteers and post-vasectomy patients identifies over 2000 proteins and candidate biomarkers of the urogenital system. J Proteome Res (2011) 1.29